BioRestorative Therapies, Inc. 9OF.F Stock
BioRestorative Therapies, Inc. Price Chart
BioRestorative Therapies, Inc. 9OF.F Financial and Trading Overview
BioRestorative Therapies, Inc. stock price | 1.83 EUR |
Previous Close | 4.96 EUR |
Open | 5.1 EUR |
Bid | 5.1 EUR x N/A |
Ask | 5.3 EUR x N/A |
Day's Range | 5.1 - 5.1 EUR |
52 Week Range | 2.44 - 5.65 EUR |
Volume | 800 EUR |
Avg. Volume | 14 EUR |
Market Cap | 20.61M EUR |
Beta (5Y Monthly) | 62.161266 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.7 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
9OF.F Valuation Measures
Enterprise Value | 7.19M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 152.54097 |
Price/Book (mrq) | 1.4261745 |
Enterprise Value/Revenue | 53.235 |
Enterprise Value/EBITDA | -0.368 |
Trading Information
BioRestorative Therapies, Inc. Stock Price History
Beta (5Y Monthly) | 62.161266 |
52-Week Change | 42.94% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.65 EUR |
52 Week Low | 2.44 EUR |
50-Day Moving Average | 4.07 EUR |
200-Day Moving Average | 3.2 EUR |
9OF.F Share Statistics
Avg. Volume (3 month) | 14 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 3.89M |
Float | 2.72M |
Short Ratio | N/A |
% Held by Insiders | 23.44% |
% Held by Institutions | 21.51% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -14581.29% |
Gross Margin | 100.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -70.35% |
Return on Equity (ttm) | -115.10% |
Income Statement
Revenue (ttm) | 135.1K EUR |
Revenue Per Share (ttm) | 0.04 EUR |
Quarterly Revenue Growth (yoy) | 95.59% |
Gross Profit (ttm) | 119.8K EUR |
EBITDA | -19565444 EUR |
Net Income Avi to Common (ttm) | -19362840 EUR |
Diluted EPS (ttm) | -4.94 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 12.37M EUR |
Total Cash Per Share (mrq) | 3.18 EUR |
Total Debt (mrq) | 268.36K EUR |
Total Debt/Equity (mrq) | 1.99 EUR |
Current Ratio (mrq) | 27.175 |
Book Value Per Share (mrq) | 3.576 |
Cash Flow Statement
Operating Cash Flow (ttm) | -6624867 EUR |
Levered Free Cash Flow (ttm) | 110.14K EUR |
Profile of BioRestorative Therapies, Inc.
Country | Germany |
State | NY |
City | Melville |
Address | 40 Marcus Drive |
ZIP | 11747 |
Phone | 631 760 8100 |
Website | https://www.biorestorative.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 10 |
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Q&A For BioRestorative Therapies, Inc. Stock
What is a current 9OF.F stock price?
BioRestorative Therapies, Inc. 9OF.F stock price today per share is 1.83 EUR.
How to purchase BioRestorative Therapies, Inc. stock?
You can buy 9OF.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioRestorative Therapies, Inc.?
The stock symbol or ticker of BioRestorative Therapies, Inc. is 9OF.F.
Which industry does the BioRestorative Therapies, Inc. company belong to?
The BioRestorative Therapies, Inc. industry is Biotechnology.
How many shares does BioRestorative Therapies, Inc. have in circulation?
The max supply of BioRestorative Therapies, Inc. shares is 8.21M.
What is BioRestorative Therapies, Inc. Price to Earnings Ratio (PE Ratio)?
BioRestorative Therapies, Inc. PE Ratio is now.
What was BioRestorative Therapies, Inc. earnings per share over the trailing 12 months (TTM)?
BioRestorative Therapies, Inc. EPS is -1.7 EUR over the trailing 12 months.
Which sector does the BioRestorative Therapies, Inc. company belong to?
The BioRestorative Therapies, Inc. sector is Healthcare.